U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 6 of 6 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



PF-03654746 is a potent, selective antagonist of the human H3 receptor, developed by Pfizer. It was in the clinical trial phase II for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, Tourette syndrome as well as poten...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

4-Bromo-2-fluorobenzyl bromide is used for the organic synthesis. It is an intermediate useful in the preparation of angiotensin II antagonists and the retinoic acid receptor–related orphan receptors inverse agonists.
Status:
Possibly Marketed Outside US
First approved in 2021

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



PF-03654746 is a potent, selective antagonist of the human H3 receptor, developed by Pfizer. It was in the clinical trial phase II for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, Tourette syndrome as well as poten...